Osteoporosis treatment and its current challenges

Finding out about Osteoporosis and its treatment
on Wed 2 Sep


Osteoporosis is recognised as a common disease of major importance in day to day health care. It is a disease of our ageing Western civilisation and its consequences - fractured wrist, vertebra or hip - are associated with chronic illness and indeed death. The statistics are pretty thought provoking:


  • A 50-year old woman has a 40% lifetime risk of sustaining a fragility fracture. 
  • 1 in 3 women and 1 in 9 men older than 80 years will sustain a hip fracture
  • 15-20% of these patients will die from complications of that event. 



Osteoporosis is characterised by low bone mass and the deterioration of the bones’ structural formation and this leads to increased fragility and the risk of fracture.  



The diagnosis is based upon a simple scan called dual-energy x-ray absorptiometry (DXA) which measures bone mineral density (BMD) at the hip, spine and wrist. This provides a T score which compares the patients’ bone density with the peak bone mass of the population.


A statistical term called the T score is calculated and a score ?2.5 is defined as osteoporosis whilst a score between -2.5 and -1.0 defines osteopenia which is a low bone density but not in the osteoporotic zone. The relative risk of fracture increases as BMD decreases.


The Diagnostic Approach

The diagnostic approach to patients who have been identified as possibly having osteoporosis is to:

  • Exclude  metabolic, genetic or malignant diseases that can mimic osteoporosis
  • Determine any secondary causes or contributory factors
  • Provide the ability to select the most appropriate treatment
  • Provide base-line information in order to monitor the ongoing response to treatment  


Known risk factors for osteoporosis are advanced age, previous low-trauma fracture, long-term steroid therapy, low body weight, family history of hip fracture, cigarette smoking and excess alcohol intake.


There’s no evidence that population-wide screening and medical intervention is effective in reducing fracture risk but clearly advice to increase physical activity, increase calcium intake, stop smoking and reduce alcohol intake is necessary.


The Fracture Risk Assessment Tool (FRAX) estimates the 10-year probability of hip fracture or major osteoporotic fractures combined (hip, spine, shoulder, or wrist) for an untreated woman or man. It uses easily obtainable clinical risk factors for fracture and can be used to determine which patients benefit from treatment.


The Management Approach

The management approach to osteoporosis includes

  • symptomatic treatment of pain associated with fractures
  • recognition of the importance of fall prevention in the elderly
  • treatment for any identified underlying cause
  • treatment to reduce future fracture risk.


Osteoporosis Treatment

Calcium and vitamin D supplementation together with a fall assessment - including the provision of hip protectors - should be offered to all women aged over 80 years.  Approximately 1200 mg of calcium (total diet plus supplement) and 1000 international units of vitamin D daily are generally suggested


Hormone replacement therapy (HRT) has recently become less popular as a first-line approach in post-menopausal women because of the increased risk of breast cancer, stroke, venous thromboembolism and perhaps ischaemic heart disease. 


The most widely used treatments for osteoporosis are anti-resorptive agents called the bisphosphonates,  which inhibit bone resorption, reduce the rate of bone turnover and prevent further bone loss.  Fracture risk can be reduced by approximately 50% with these agents.


For most post-menopausal women with osteoporosis, oral bisphosphonates (alendronate or risedronate) are first-line therapy. Intravenous zoledronic acid has been demonstrated to reduce vertebral and hip fractures and is a good alternative for individuals with gastrointestinal intolerance to oral bisphosphonates.


Denosumab is a fully human monoclonal antibody which decreases bone resorption, increases bone mineral density (BMD), and reduces the risk of fracture.  It could be used as initial therapy in certain patients at high risk for fracture, such as older patients who have difficulty with the dosing requirements of oral bisphosphonates or who are intolerant of or unresponsive to other therapies and in those with impaired kidney function.


Raloxifene is a selective oestrogen-receptor modulator which can be useful for patients who cannot tolerate any bisphosphonates or for women with osteoporosis and increased risk of invasive breast cancer. Parathyroid hormone (PTH) is an anabolic agent and, in contrast to anti-resorptive agents, stimulates bone formation and activates bone remodelling. It needs to be injected subcutaneously daily and is typically used in patients for whom other osteoporosis therapies fail.


Unfortunately, the best way to use the various osteoporosis treatment options remains unclear.  Questions that remain unanswered include:


  1. Is combined or sequential treatment justified?
  2. Should treatment be monitored by periodic bone mineral density measurements?
  3. Should there be drug holidays?
  4. What is the correct length of time that patients should be treated with the various therapies?
  5. What are the best treatment options in men or pre-menopausal women?


The current situation

Current data about patients with osteoporosis is not very positive:

  • It demonstrates low use of treatments and compliance in patients who have established osteoporosis. 
  • Availability of DXA scanning and specialist nurse support in primary care remains an issue.
  • Some patients still leave hospital after treatment for a fragility fracture without any assessment of bone density or plan for treatment of osteoporosis.


There’s no question that the hesitation to address the management of osteoporosis must be resolved. Prevention, detection and treatment are essential particularly for post-menopausal women who have the greatest risk.



Although every effort is made to ensure that all health advice on this website is accurate and up to date it is for information purposes and should not replace a visit to your doctor or health care professional.

As the advice is general in nature rather than specific to individuals Dr Vanderpump cannot accept any liability for actions arising from its use nor can he be held responsible for the content of any pages referenced by an external link.



acanthosis nigricans Acromegaly Addison's disease adolescent diabetes problems adolescent thyroid problems Adrenal crisis adrenal fatigue Adrenal glands Anovulation artificial pancreas Autoimmune Thyroiditis Bariatric Surgery blood glucose levels blood pressure breastfeeding CAH Charcot foot cholesterol CHT coffee cold and flu medications Conception Congenital adrenal hyperplasia congenital hypothyroidism Consultant Endocrinologist London coronavirus cortisol covid-19 Cushing's disease Cushing's syndrome Depression Diabetes diabetes and bone health diabetes and heart health diabetes and oral health diabetes and parkinsons diabetes and sexual dysfunction diabetes and skin conditions diabetes and thrush diabetes in China diabetes insipidus diabetes latest diabetic ketoacidosis diabetic neuropathy Diabetic prevalence diabetic retinopathy diet for diabetes diet for obesity Disability Act Down's Syndrome Dr Mark Vanderpump e-consulting endocrine system fertility folic acid Freestyle Libre frozen shoulder and thyroid Fruit sugars gestational diabetes Gigantism Glucose Monitoring Glucose Tolerance Test gluten free Goitre Graves Disease Graves Orbitopathy guthrie test hair loss Hashimoto's Disease healthcare services hearing loss Heart Disease heel prick test Hepatitis C Hormones - most important how to lose weight hyperparathyroidism Hypersecretion Hyperthyroidism hyperthyroidism and respiratory problems Hypocalcaemia Hypogonadism hypoparathyroidism hypophysitis Hyposecretion Hypothyroidism hypothyroidism and respiratory problems IFG IGT immunotherapy side effects Impaired Fasting Glucose Impaired Glucose Tolerance Insulin Resistance Iodine IR iron Labour and birth late onset hypogonadism Levothyroxine Long Covid losing weight Low testosterone Mark Vanderpump MEN1 MEN2 menopause metabolic syndrome mood changes morning sickness Multiple endocrine neoplasia neuroendocrine tumour neuropathy Obesity obstructive sleep apnoea older patients online doctor OSA Osteoporosis overactive thyroid ozempic Pancreas Pancreatic Cancer Pancreatic Diabetes parathyroid glands Patient Resources Patient Support Groups PCOS PCOS and acne PCOS and fertility PCOS and Insulin PCOS diet Phaeochromocytomas Pituitary Gland POF Polycystic Ovary Syndrome Post menopause thyroid problem Post pregnancy thyroid problem postnatal diabetes medication postnatal thyroid medication Prader-Willi Syndrome pre-eclampsia prediabetes pregnancy Pregnancy and Diabetes Pregnancy and Thyroid Disease Premature Ovarian Failure prolactinomas PTH puberty Radioactive Iodine RAI resistant hypertension semaglutide Sheehan's Syndrome Skin tags sleep and diabetes sleep and obesity soy Soya steroid dependent subacute thyroiditis T4 Tara Palmer Tomkinson testosterone Tetany The endocrine system Thyroid thyroid and menstruation thyroid cancer Thyroid disease in children thyroid nodules Thyroid Storm thyroid tests Thyroiditis Thyrotoxic Periodic Paralysis Thyroxine TSH levels TSH Testing tumours Type 1 diabetes Type 2 Diabetes Type 3 diabetes underactive thyroid Vitamin B complex Vitamin D Waist circumference weight gain weightloss

Please get in touch

Phone: 07565 978310

Contact form